Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

EuroPCR 2019 | Long-Term Follow-Up for New Left Bundle Branch Block After TAVR Is Reassuring with Certain Precautions

Long-term follow-up of patients who underwent transcatheter aortic valve replacement (TAVR) and developed left bundle branch block (LBBB) after the procedure seems reassuring. Although it is not benign, it is associated with more conduction defects, more pacemakers, and worsening ventricular function.

Long-term follow-up “partially reassures” the concerns of many physicians about new LBBB after TAVR.

While roughly one in five patients developed a conduction disturbance, there was no difference in clinical events, including mortality or heart failure hospitalizations, at 3 years between patients with new LBBB and those who did not develop LBBB. In any case, there was a higher rate of pacemaker implantation and a reduction in ejection fraction among those who developed new LBBB. Patients who required a pacemaker mainly did it during the first year.

The incidence of LBBB depends on the study, device type, implantation techniques, and patient comorbidities, but data mainly point towards an association with self-expanding valves.


Read also: EuroPCR 2019 | REVELATION: Drug Coated Balloons in ST Elevation MI.


This new study, presented at EuroPCR 2019 and published simultaneously in JACC: Cardiovascular Interventions, included 1415 consecutive patients who underwent TAVR with a balloon-expandable valve (Sapien, Sapien XT, or Sapien 3; Edwards Lifesciences) or a self-expanding valve (CoreValve or Evolut R; Medtronic) at nine sites between 2007 and 2015.

The final analysis included 1020 cases, since 395 patients were excluded due to failed implantation, conversion to surgery, procedural death, or, in most cases, the implantation of a pacemaker during the index hospitalization.

New LBBB occurred in 461 patients immediately after device release and, of these, LBBB persisted in 212 patients (20.1%). The incidence of LBBB was significantly higher among patients with CoreValve/Evolut R devices.

At 3 years, there was no significant difference in all-cause mortality, cardiovascular mortality, sudden death, or heart failure hospitalizations between those who developed LBBB and those who did not.


Read also: EuroPCR 2019 | TRILUMINATE: Tricuspid Repair with Clip Improves Regurgitation and Quality of Life.


There was a difference in pacemaker implantation (15.5% vs. 5.4%; hazard ratio [HR]: 2.45) and it was highest in the first study year, when the risk tripled.

The mean time for pacemaker implantation was 8 months and, after the first year, rates of pacemaker implantation were similar for both groups.

Original Title: Long-term outcomes in patients with new-onset persistent left bundle branch block following TAVR.

Reference: Chamandi C et al. J Am Coll Cardiol Intv. 2019; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

SCAI 2026 | Can an atrial fixation device prevent complications of transcatheter mitral valve replacement? Analysis of the AltaValve system

Transcatheter mitral valve replacement (TMVR) represents one of the most complex areas within structural interventions. Unlike TAVI, where valvular anatomy typically provides more predictable...

Beyond TAVI: Cardiac Rehabilitation as a Determinant of Clinical Outcomes

Aortic stenosis is an increasingly prevalent condition associated with population aging, with a prevalence of approximately 3.4% in individuals over 75 years of age...

Comparative outcomes between transaxillary approach and thoracotomy-based approaches in TAVI with alternative access

TAVI has become the standard treatment for high-risk aortic stenosis. When transfemoral access is not feasible (approximately 10–15%), alternative approaches are used: transaxillary (subclavian...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

SCAI 2026 | Deep vein arterialization as an alternative in patients with critical limb ischemia without conventional options

Critical limb ischemia (CLI) represents one of the most advanced stages of peripheral arterial disease (PAD). In a significant proportion of patients, distal anatomy,...

SCAI 2026 | Can an atrial fixation device prevent complications of transcatheter mitral valve replacement? Analysis of the AltaValve system

Transcatheter mitral valve replacement (TMVR) represents one of the most complex areas within structural interventions. Unlike TAVI, where valvular anatomy typically provides more predictable...

SCAI 2026 | SELUTION DeNovo subanalysis: Use of sirolimus-eluting balloon in acute coronary syndrome

Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation remains the predominant strategy in the setting of acute coronary syndrome (ACS). However, in recent...